Guideline:
Bibliographic Source(s)
- Finnish Medical Society Duodecim. Differential diagnosis of chest pain. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki Finland: Wiley Interscience. John Wiley & Sons; 2008 May 16 [Various].
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: Finnish Medical Society Duodecim. Differential diagnosis of chest pain. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki Finland: Wiley Interscience. John Wiley & Sons; 2004 Sep 14 [Various].
Guideline Category
Diagnosis
Intended Users
Health Care Providers
Physicians
Guideline Objective(s)
Evidence-Based Medicine Guidelines collect summarize and update the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given recommendations.
Target Population
Individuals with chest pain
Interventions and Practices Considered
Differential Diagnosis of Chest Pain
- Recognizing typical characteristics of myocardial ischemic pain
- Electrocardiography (ECG) as key examination
- Measurement of markers of myocardial injury (cardiac troponins T and I creatine kinase [CK]-MB mass)
- Recognizing minor ECG changes suggestive of myocardial infarction (MI)
- Recognizing non-ischemic causes of chest pain
- Recognizing ECG changes resembling those of an MI
Major Outcomes Considered
Not stated
Methods Used to Collect/Select Evidence
Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases
Description of Methods used to Collect/Select the Evidence
The evidence reviewed was collected from the Cochrane database of systematic reviews and the Database of Abstracts of Reviews of Effectiveness (DARE). In addition the Cochrane Library and medical journals were searched specifically for original publications.
Number of Source Documents
Not stated
Methods Used to Assess the Quality and Strength of the Evidence
Weighting According to a Rating Scheme (Scheme Given)
Rating Scheme for the Strength of the Evidence
Classification of the Quality of Evidence
| Code | Quality of Evidence | Definition |
|---|---|---|
| A | High | Further research is very unlikely to change our confidence in the estimate of effect.
|
| B | Moderate | Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.
|
| C | Low | Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.
|
| D | Very Low | Any estimate of effect is very uncertain.
|
GRADE (Grading of Recommendations Assessment Development and Evaluation) Working Group 2007 (modified by the EBM Guidelines Editorial Team).
Methods Used to Analyze the Evidence
Systematic Review
Description of the Methods Used to Analyze the Evidence
Not stated
Methods Used to Formulate the Recommendations
Not stated
Rating Scheme for the Strength of the Recommendations
Not applicable
Cost Analysis
A formal cost analysis was not performed and published cost analyses were not reviewed.
Method of Guideline Validation
Peer Review
Description of Method of Guideline Validation
Not stated
Major Recommendations
Objectives
- Pain caused by myocardial ischaemia or impending infarction must be differentiated from nonischaemic chest pain. Nonischaemic pain may be caused by other severe conditions that require acute treatment such as pericarditis aortic dissection and pulmonary embolism.
- Remember that patients at risk can have ischaemic chest pain in addition to nonischaemic chest pain.
- Differentiate between stable and unstable angina (see the Finnish Medical Society Duodecim guideline "Acute Coronary Syndromes: Unstable Angina Pectoris and Non-ST Segment Elevation Myocardial Infarction [NSTEMI]").
Myocardial Ischaemic Pain
- The main feature of myocardial ischaemia (impending infarction) is usually prolonged chest pain. Typical characteristics of the pain include:
- Duration usually over 20 minutes
- Located in the retrosternal area possibly radiating to the arms (usually to the left arm) back neck or the lower jaw
- Described as pressing or heavy or as a sensation of a tight band around the chest; breathing or changing posture does not notably influence the severity of the pain
- Continuous with constant intensity
- Symptoms (pain beginning in the upper abdomen nausea) may resemble the symptoms of acute abdomen. Nausea and vomiting are sometimes the main symptoms especially in inferoposterior wall ischaemia.
- In inferoposterior wall ischaemia vagal reflexes may cause bradycardia and hypotension presenting as dizziness or fainting.
- Electrocardiogram (ECG) is the key examination during the first 4 hours after pain onset but a normal ECG does not rule out an imminent infarction.
- Markers of myocardial injury (cardiac troponins T and I creatine kinase(CK)-MB mass) start to rise about 4 hours after pain onset. An increase of these markers is diagnostic of myocardial infarction irrespective of ECG findings (see the Finnish Medical Society Duodecim guideline "Myocardial Infarction").
- Minor signs of myocardial infarction in ECG see Table 1 in the original guideline document.
Nonischaemic Causes of Chest Pain
- For nonischaemic causes of chest pain see Table below entitled "Nonischaemic Causes of Chest Pain".
- For ECG changes resembling those of a myocardial infarction (MI) see Table below entitled "ECG Changes Resembling Those of an MI")
Table. Nonischaemic Causes of Chest Pain
| Illness/Condition | Differentiating Symptoms and Signs |
|---|---|
| Reflux oesophagitis oesophageal spasm |
|
| Pulmonary embolism |
|
| Hyperventilation | Hyperventilation Syndrome
|
| Spontaneous pneumothorax |
|
| Aortic dissection |
|
| Pericarditis |
|
| Pleuritis |
|
| Costochondral pain |
|
| Early herpes zoster |
|
| Ectopic beats |
|
| Peptic ulcer cholecystitis pancreatitis |
|
| Depression |
|
| Alcohol-related |
|
Table. ECG Changes Resembling Those of an MI
| ST Changes Resembling Those of Acute Ischaemia | |
|---|---|
| ST segment elevation | Early repolarization in V1–V3. Seen particularly in athletic men ("athlete's heart") Acute myopericarditis in all leads except V1 aVR. Not resolved with a beta-blocker. Pulmonary embolism – in inferior leads Hyperkalaemia Hypertrophic cardiomyopathy |
| ST segment depression | Sympathicotonia Hyperventilation Pulmonary embolism Hypokalaemia Digoxin Antiarrhythmics Psychiatric medication Hypertrophic cardiomyopathy Reciprocal ST depression of an inferior infarction in leads V2–V3–V4 Circulatory shock |
| QRS changes resembling those of Q wave infarction | Hypertrophic cardiomyopathy Wolff-Parkinson-White (WPW) syndrome Myocarditis Blunt cardiac injury Massive pulmonary embolism (QS in leads V1–V3) Pneumothorax Cardiac amyloidosis Cardiac tumours Progressing muscular dystrophy Friedreich's ataxia |
| ST changes resembling those of a non-Q wave infarction | Increased intracranial pressure–subarachnoid bleed – skull injury Hyperventilation syndrome Post-tachyarrhythmia state Circulatory shock – haemorrhage – sepsis Acute pancreatitis Myopericarditis |
Related Resources
Refer to the original guideline document for related evidence including Cochrane reviews and other evidence summaries.
Definitions:
Classification of the Quality of Evidence
| Code | Quality of Evidence | Definition |
|---|---|---|
| A | High | Further research is very unlikely to change our confidence in the estimate of effect.
|
| B | Moderate | Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.
|
| C | Low | Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.
|
| D | Very Low | Any estimate of effect is very uncertain.
|
GRADE (Grading of Recommendations Assessment Development and Evaluation) Working Group 2007 (modified by the EBM Guidelines Editorial Team).
Clinical Algorithm(s)
None provided
Type of Evidence supporting the Recommendations
Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are.
Potential Benefits
Appropriate differential diagnosis of chest pain
Potential Harms
Not stated
Description of Implementation Strategy
An implementation strategy was not provided.
IOM Care Need
Getting Better
Staying Healthy
IOM Domain
Effectiveness
Bibliographic Source(s)
- Finnish Medical Society Duodecim. Differential diagnosis of chest pain. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki Finland: Wiley Interscience. John Wiley & Sons; 2008 May 16 [Various].
Adaptation
Not applicable: The guideline was not adapted from another source.
Source(s) of Funding
Finnish Medical Society Duodecim
Guideline Committee
Editorial Team of EBM Guidelines
Composition of Group that Authored the Guideline
Primary Author: Editors
Financial Disclosures/Conflicts of Interest
Not stated
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: Finnish Medical Society Duodecim. Differential diagnosis of chest pain. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki Finland: Wiley Interscience. John Wiley & Sons; 2004 Sep 14 [Various].
Guideline Availability
This guideline is included in "EBM Guidelines. Evidence-Based Medicine" available from Duodecim Medical Publications Ltd PO Box 713 00101 Helsinki Finland; e-mail: info@ebm-guidelines.com; Web site: www.ebm-guidelines.com.
Availability of Companion Documents
None available
Patient Resources
None available
NGC STATUS
This summary was completed by ECRI on August 28 2001. The information was verified by the guideline developer as of October 26 2001. This summary was updated by ECRI on April 2 2004 October 1 2004 and most recently on February 21 2005. This summary was updated by ECRI Institute on September 30 2008.
COPYRIGHT STATEMENT
This NGC summary is based on the original guideline which is subject to the guideline developer's copyright restrictions.
NGC Disclaimer
The National Guideline Clearinghouse™ (NGC) does not develop produce approve or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies relevant professional associations public or private organizations other government agencies health care organizations or plans and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .
NGC AHRQ and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC AHRQ or its contractor ECRI Institute and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.
Tools
No Quick Reference tools have been developed.

